Clinical Trial Update: Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)

View source ↗

Summary

An update on a real-world study evaluating Rebif with a new formulation, focusing on safety, tolerability, and patient adherence in relapsing-remitting multiple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Rebif (interferon beta-1a)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Multiple Sclerosis, Relapsing Remitting | Status: COMPLETED